The company said total revenue for Q1 2024 rose to $11.9 billion, up 5% (6% when adjusted for foreign exchange). Growth Portfolio revenue increased 8% to $4.8 billion (11% when adjusted for foreign exchange).

1. 01

   The company said total revenue for Q1 2024 rose to $11.9 billion, up 5% (6% when adjusted for foreign exchange). Growth Portfolio revenue increased 8% to $4.8 billion (11% when adjusted for foreign exchange).

2. 02

   Bristol-Myers Squibb said Acquired IPRD charges rose to $12.9 billion in Q1 from $75 million a year earlier. The company reported a GAAP loss per share of $(5.89) and a non-GAAP loss per share of $(4.40), and said the net impact of Acquired IPRD charges and licensing income was $(6.30) per share.

3. 03

   Bristol Myers Squibb said its GAAP gross margin fell from 77.4% to 75.3% in Q1, and its non-GAAP gross margin fell from 77.8% to 75.5%. The company cited product mix as the main factor.

4. 04

   BMY said it revised its non-GAAP diluted EPS outlook for 2024 to $0.40–$0.70 from $7.10–$7.40. The company said the revision reflects the $(6.73) total deals impact, and it put the non-GAAP effective tax rate at about 69%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.